FDA approves Aqneursa for ataxia in ataxia-telangiectasia

Aqneursa, or levacetylleucine, is indicated for adults and children weighing at least 15 kilograms. The approval concerns this neurological symptom; it does not establish a cure for the inherited disorder. [1] [2]

The supporting trial enrolled 73 people and compared the medicine with placebo in two successive 12-week periods. Randomization determined the order of treatment and placebo. The principal functional scale assesses gait, sitting, stance and speech, with lower scores indicating better neurological status. The FDA reports better scores during treatment. [1]

The prescribing information puts a magnitude on that result: the treatment difference was −0.6 points, with a 95% confidence interval from −0.9 to −0.2, on a scale running from zero to sixteen. This is an average comparison across the study, not a forecast of an individual patient’s improvement. The company also provides prescription-enrollment and insurance-support materials. Their existence does not establish any particular patient’s coverage or out-of-pocket cost. [3] [4]

For a family, the useful conversation with the treating clinician is therefore specific: which daily functions might reasonably improve, how those changes would be assessed, and how treatment fits the patient’s other medicines and care. Safety remains part of that discussion. The FDA lists falls, skin lacerations and urinary tract infections among common adverse reactions, and warns of possible fetal harm from animal evidence. [1] The advance is a new, testable treatment option for a defined group, with expectations anchored to what the trial measured.